137 results
8-K/A
EX-99.1
CMMB
Chemomab Therapeutics Ltd
14 Apr 21
UNAUDITED PRO FORMA Condensed COMBINED FINANCIAL STATEMENTS
11:50am
, the nature and amount of any adjustments to the historical financial statements of Anchiano to conform its accounting policies to those of Chemomab … and $1.0 million in intellectual property research and development. Further, given the nature of the transaction no step-up in basis or goodwill
8-K
CMMB
Chemomab Therapeutics Ltd
24 Apr 20
Submission of Matters to a Vote of Security Holders
4:38pm
committee the authority to fix the said independent auditors’ remuneration in accordance with the volume and nature of their services.
FOR
AGAINST
ABSTAIN … ’ remuneration in accordance with the volume and nature of their services.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
DRS
EX-10.7
CMMB
Chemomab Therapeutics Ltd
28 Sep 18
Draft registration statement
12:00am
management policy; the size of the Company and the nature of its activities; and with respect to the terms of office and employment that comprise … overview and according to the officers’ duties.
The Compensation Policy was prepared taking into account the size and nature of the Company as an active
F-1
EX-10.7
CMMB
Chemomab Therapeutics Ltd
7 Jan 19
Registration statement (foreign)
5:11pm
management policy; the size of the Company and the nature of its activities; and with respect to the terms of office and employment that comprise … and according to the officers’ duties.
The Compensation Policy was prepared taking into account the size and nature of the Company as an active
DEFA14A
EX-2.1
46qy yaz1
15 Dec 20
Additional proxy soliciting materials
3:32pm
S-4
EX-2.1
s2e24
13 Jan 21
Registration of securities issued in business combination transactions
9:30am
8-K
EX-2.1
rcez 6bvruv2x9
15 Dec 20
Anchiano Therapeutics and Chemomab Announce Entry Into
3:34pm
6-K
5ixza3v
8 Jul 19
Current report (foreign)
7:30am
PRE 14A
uk893 8eh0893
30 Mar 20
Preliminary proxy
5:03pm
6-K
EX-99.1
5zegvt7t6er3foo81 vk
28 May 19
Notice of Annual General Meeting of Shareholders of the Company
5:26pm
6-K
EX-99.3
g0bmmor762qac3 6kgq
28 May 19
Notice of Annual General Meeting of Shareholders of the Company
5:26pm
8-K
EX-10.1
vafyk v4y4n36cjvrbk
15 Dec 20
Anchiano Therapeutics and Chemomab Announce Entry Into
3:34pm
F-1/A
EX-10.3
jfc0ugwzvh qpu
5 Feb 19
Registration statement (foreign) (amended)
5:30pm
8-K
qosl2bsvrap85xsyoc
31 Jan 20
Other Events
5:01pm
8-K
4wilnnk h26z8vqxbr6
16 Mar 20
Other Events
4:32pm
8-K
EX-10.2
h9n63 njti
15 Dec 20
Anchiano Therapeutics and Chemomab Announce Entry Into
3:34pm
S-4
EX-10.9
0p8zhd sel
13 Jan 21
Registration of securities issued in business combination transactions
9:30am
DEF 14A
xxu3 ki0f8z
6 Apr 20
Definitive proxy
6:11am